Merck beats quarterly estimates on strength of Keytruda and new products, narrows outlook
Merck narrowed its 2026 sales guidance and hiked its adjusted profit outlook.
AI brief
Pulse reads the full article- What happened
- Why it matters
- What to watch
Sign in to get the AI brief. Pulse explains what happened, why it matters, what to watch and who's exposed. Free for members.
Sign in to read the brief
